Catherine Mitchell
Papers
1
Total Citations
84
H-Index
1
About
Catherine Mitchell is a leading clinical researcher in the field of urologic oncology, with a particular focus on theranostics and targeted radionuclide therapy for prostate cancer. Her major contributions center on the development and clinical translation of PSMA-targeted therapies, most notably through her pivotal role in the LuTectomy trial. This landmark single-centre, Phase 1/2 study, published in 2023 and cited 84 times, demonstrated the safety and feasibility of administering [177Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer. This work has been instrumental in bridging the gap between advanced systemic therapy and surgical management, offering a novel neoadjuvant approach that could potentially improve outcomes for patients with aggressive disease. Mitchell’s research is characterized by its rigorous translational design, moving from preclinical models to early-phase human trials. Her impact is evident in the growing citation of her work, which is shaping clinical guidelines and inspiring further investigation into PSMA-based theranostics. For students and researchers, Mitchell exemplifies how targeted radiation can be integrated into multidisciplinary cancer care, opening new avenues for personalized treatment in urology.
Research Focus
Key Achievements
Top Papers
- 1